Axa S.A. Achilles Therapeutics PLC Transaction History

Axa S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.84 - $1.26 $2,020 - $3,030	-2,405 Reduced 0.85%	282,028 $270,000
Q4 2022 Feb 14, 2023	SELL	$0.79 - $2.39 $1,124 - $3,400	-1,423 Reduced 0.5%	284,433 $255,000
Q3 2022 Feb 14, 2023	BUY	$2.26 - $3.38 $4,974 - $7,439	2,201 Added 0.78%	285,856 $811,000
Q3 2022 Nov 14, 2022	BUY	$2.26 - $3.38 $4,974 - $7,439	2,201 Added 0.78%	285,856 $646,000
Q2 2022 Feb 14, 2023	BUY	$1.96 - $3.04 $1,624 - $2,520	829 Added 0.29%	283,655 $714,000
Q2 2022 Aug 15, 2022	BUY	$1.96 - $3.04 $1,624 - $2,520	829 Added 0.29%	283,655 $715,000
Q1 2022 Feb 14, 2023	SELL	$2.8 - $5.23 $8,484 - $15,846	-3,030 Reduced 1.06%	282,826 $831,000
Q1 2022 May 13, 2022	BUY	$2.8 - $5.23 $8 - $15	3 Added 0.0%	282,826 $832,000
Q4 2021 Feb 14, 2022	BUY	$4.22 - $8.86 $14,217 - $29,849	3,369 Added 1.21%	282,823 $1.42 Million
Q3 2021 Nov 15, 2021	BUY	$5.81 - $9.93 $59,953 - $102,467	10,319 Added 3.83%	279,454 $2.18 Million
Q2 2021 Aug 13, 2021	BUY	$9.79 - $17.86 $2.63 Million - $4.81 Million	269,135 New	269,135 $2.64 Million

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.